Hydrogen-Rich Water Shows Early Promise for ME/CFS Fatigue Relief

ME/CFS affects millions worldwide and is characterized by profound fatigue, post-exertional malaise, cognitive impairment, and autonomic dysfunction. Despite its severity, no FDA-approved treatments exist, and conventional care is limited to symptom management. This narrative mini-review by Friedberg and LeBaron examines the mechanistic rationale and early clinical evidence for molecular hydrogen (H2), administered as hydrogen-rich water (HRW), as an adjunctive therapy for ME/CFS.

The mechanistic case for H2 in ME/CFS is multifaceted. Unlike conventional antioxidants, H2 selectively scavenges only the most cytotoxic reactive oxygen species — hydroxyl radicals and peroxynitrite — while preserving beneficial redox signaling molecules. It also downregulates pro-inflammatory cytokines IL-6 and TNF-α via NF-κB pathway inhibition, directly relevant given elevated cytokine levels documented in ME/CFS subgroups. Critically, H2 targets mitochondrial complex III via the Rieske iron-sulfur protein, transiently suppressing ATP production and triggering a mitohormetic response that ultimately enhances mitochondrial resilience. Additional neuroprotective and autonomic modulation effects have been observed in healthy volunteers, including changes in heart rate variability.

Three developmental clinical trials have tested HRW in ME/CFS, all led by the same team. The first 4-week RCT used a high dose (~12 mg H2/day) and found no significant benefits, with roughly half of participants experiencing moderate-to-severe adverse effects including headaches and GI discomfort — possibly attributable to the non-standard high dose or the short duration. The second trial reduced the dose (~7.5 mg/day, three times daily) over 8 weeks in a remote RCT with a heart rhythm biofeedback comparator arm; HRW produced small but statistically significant improvements in fatigue and physical function with milder side effects. The third and most recent trial extended treatment to 16 weeks, comparing standard dosing throughout versus a dose-escalation protocol. Both arms showed statistically significant and clinically meaningful improvements in fatigue and physical function; only the standard-dose group additionally improved depression and anxiety scores. No significant changes in salivary uric acid — a hypothesized biomarker — were detected.

Findings from a 14-day placebo-controlled Long COVID trial (Tan et al.) reinforce the translational relevance: HRW significantly reduced fatigue scores and improved 6-minute walk test distance, suggesting shared oxidative and inflammatory pathophysiology between Long COVID and ME/CFS that H2 may address.

The authors call for larger, rigorously controlled trials integrating objective biomarker collection. Portable capillary blood sampling devices (e.g., Tasso+, TAP) now enable remote metabolomics assessments, offering a practical path to biomarker discovery in homebound ME/CFS patients. Standardized dosing protocols, blinding procedures, and frequent digital symptom diaries to reduce recall bias are also recommended priorities for the next generation of HRW trials.